Superoxide differentially controls pulmonary and systemic vascular tone through multiple signalling pathways.
OBJECTIVE
the aim of this study was to determine the relative importance of Ca(2+) sensitization, ion channels, and intracellular Ca(2+) ([Ca(2+)](i)) in the mixed constrictor/relaxation actions of superoxide anion on systemic and pulmonary arteries.


RESULTS
pulmonary and mesenteric arteries were obtained from rat. Superoxide was generated in arteries and cells with 6-anilino-5,8-quinolinequinone (LY83583). Following pre-constriction with U46619, 10 μmol/L LY83583 caused constriction in pulmonary and relaxation in mesenteric arteries. Both constrictor and relaxant actions of LY83583 were inhibited by superoxide dismutase and catalase. LY83583 caused Rho-kinase-dependent constriction in α-toxin-permeabilized pulmonary but not mesenteric arteries. Phosphorylation of myosin phosphatase-targeting subunit-1 (MYPT-1; as determined by western blot), was enhanced by LY83583 in pulmonary artery only. However, in both artery types, changes in tension were closely correlated with changes in phosphorylation of the 20 kDa myosin light chain as well as changes in [Ca(2+)](i) (as measured with Fura PE-3), with LY83583 causing increases in pulmonary and decreases in mesenteric arteries. When U46619 was replaced by 30 mmol/L K(+), all changes in [Ca(2+)](i) were abolished and LY83583 constricted both artery types. The K(V) channel inhibitor 4-aminopyridine abolished the LY83583-induced relaxation in mesenteric artery without affecting constriction in pulmonary artery. However, LY83583 caused a similar hyperpolarizing shift in the steady-state activation of K(V) current in isolated smooth muscle cells of both artery types.


CONCLUSIONS
superoxide only causes Rho-kinase-dependent Ca(2+) sensitization in pulmonary artery, resulting in constriction, and whilst it opens K(V) channels in both artery types, this only results in relaxation in mesenteric.
Snetkov
Vladimir A
VA
Division of Asthma, Allergy and Lung Biology, School of Medicine, King's College London, Room 3.20, Franklin Wilkins Building, Stamford Street, London SE1 9NH, UK.
Smirnov
Sergey V
SV
Kua
Justin
J
Aaronson
Philip I
PI
Ward
Jeremy P T
JP
Knock
Greg A
GA
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D015761:4-Aminopyridine / Q000494:pharmacology; D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D066298:In Vitro Techniques; D008297:Male; D008638:Mesenteric Arteries / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D010069:Oxadiazoles / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D024642:Potassium Channels, Voltage-Gated / Q000037:antagonists & inhibitors / Q000502:physiology; D011651:Pulmonary Artery / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013481:Superoxides / Q000378:metabolism*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D054460:rho-Associated Kinases / Q000378:metabolism
C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; D000634:Aminoquinolines; D010069:Oxadiazoles; D026902:Potassium Channel Blockers; D024642:Potassium Channels, Voltage-Gated; D011810:Quinoxalines; D014662:Vasoconstrictor Agents; D013481:Superoxides; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C041715:6-anilino-5,8-quinolinedione; D015761:4-Aminopyridine; D054460:rho-Associated Kinases; D006162:Guanylate Cyclase
Free Radic Biol Med. 2009 Mar 1;46(5):633-42
19103285
Circ J. 2006 Feb;70(2):174-8
16434811
Diabetes. 2004 May;53(5):1352-9
15111506
J Mol Cell Cardiol. 2004 Dec;37(6):1119-36
15572043
Physiol Rev. 2003 Oct;83(4):1325-58
14506307
Am J Respir Crit Care Med. 2008 Jan 15;177(2):219-26
17962640
Br J Pharmacol. 2000 Sep;131(1):5-9
10960061
Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1404-11
17071731
Circ Res. 2002 Oct 18;91(8):719-26
12386149
J Hypertens. 2005 Mar;23(3):571-9
15716699
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L515-29
18621909
J Hypertens. 2010 Feb;28(2):201-12
20051913
Physiol Res. 2000;49(1):107-14
10805411
Biochim Biophys Acta. 2004 Jan 5;1670(1):19-27
14729138
J Hypertens. 2005 Apr;23(4):807-14
15775786
Cardiovasc Res. 2008 Feb 1;77(3):570-9
18032393
Am J Physiol. 1997 Jun;272(6 Pt 2):H2686-92
9227547
J Pharmacol Exp Ther. 2006 Jan;316(1):42-52
16183707
Adv Exp Med Biol. 2010;661:109-22
20204726
J Cardiovasc Pharmacol. 1996 Nov;28(5):703-11
8945685
Br J Pharmacol. 2003 Mar;138(6):1085-92
12684264
Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1495-500
15371261
Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L347-60
19098127
J Pharmacol Exp Ther. 2009 Nov;331(2):404-11
19692634
Circ Res. 2003 Mar 7;92(4):411-8
12600888
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2614-21
17023676
Biochem J. 2005 Aug 1;389(Pt 3):763-74
15823093
Circ Res. 2007 Mar 30;100(6):923-9
17332430
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1762-70
12521932
Hypertens Res. 2003 Jan;26(1):97-106
12661918
Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1185-93
10993783
Br J Pharmacol. 2003 Sep;140(1):97-106
12967939
Free Radic Biol Med. 2008 Nov 15;45(10):1468-76
18805479
Free Radic Biol Med. 2008 Jul 1;45(1):1-17
18423411
Am J Physiol. 1998 Oct;275(4):H1283-9
9746477
J Physiol. 2006 Jan 1;570(Pt 1):53-8
16254010
J Cardiovasc Pharmacol. 2004 Nov;44(5):552-6
15505491
Stroke. 1993 Mar;24(3):427-34
8095358